Sab BiotherapeuticsSABS
13F holders, Q2 2025 (June 30)At the end of Q2 2025, 25 institutions reported holding Sab Biotherapeutics Inc. (SABS) in their 13F filings, down 1 from Q1 2025. 3 opened new positions and 4 sold out. The largest holders were BVF Inc. ($1.6M), Sessa Capital IM, L.P. ($805K) and Vanguard Group Inc. ($494K). 2 famous investors held it, including Ken Griffin (0.0% of Citadel Advisors's portfolio) and Jim Simons / Peter Brown (0.0% of Renaissance Technologies's portfolio).
- Company
- Sab Biotherapeutics Inc.
- CUSIP
- 78397T202
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $51K |
| Exits | 4 | $432K |
All 13F filers, Q1 2025 → Q2 2025: 46,218 shares bought and 331,896 shares sold, net −285,678 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 25 holders
| BVF Inc. | 0.06% | No change | 917,826 | $1.6M |
| Sessa Capital IM, L.P. | 0.02% | No change | 458,457 | $805K |
| Vanguard Group Inc. | 0.00% | Add +1.8% | 282,371 | $494K |
| Geode Capital Management, LLC | 0.00% | Add +0.1% | 84,772 | $148K |
| Pathstone Holdings, LLC | 0.00% | No change | 50,650 | $89K |
| NorthCoast Asset Management LLC | 0.00% | No change | 19,201 | $34K |
| First PREMIER Bank | 0.01% | No change | 18,986 | $33K |
| Citadel Advisors | 0.00% | New | 17,095 | $30K |
| Kestra Advisory Services, LLC | 0.00% | No change | 11,930 | $21K |
| Creative Planning | 0.00% | New | 11,852 | $21K |
| Northern Trust Corp. | 0.00% | No change | 11,387 | $20K |
| Renaissance Technologies | 0.00% | Add +10.0% | 11,030 | $19K |
| UBS Group AG | 0.00% | Add +13564.1% | 10,658 | $19K |
| BlackRock, Inc. | 0.00% | Reduce -68.6% | 7,006 | $12K |
| Osaic Holdings, Inc. | 0.00% | Reduce -0.2% | 4,937 | $9K |
| Sachetta, LLC | 0.00% | No change | 4,100 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Add +2035.3% | 726 | $1K |
| MAI Capital Management | 0.00% | No change | 217 | $381 |
| GS Investments, Inc. | 0.00% | No change | 200 | $351 |
| Morgan Stanley | 0.00% | Reduce -62.6% | 168 | $295 |
| JPMorgan Chase & Co. | 0.00% | Reduce -15.5% | 87 | $152 |
| Bank of America Corp. | 0.00% | Add +9.0% | 73 | $128 |
| Harbour Investments, Inc. | 0.00% | No change | 50 | $88 |
| SBI Securities Co., Ltd. | 0.00% | No change | 50 | $88 |
| Raymond James Financial Inc. | 0.00% | New | 45 | $79 |
"% of holder's portfolio" is SABS's weight in each manager's 13F, not the share of Sab Biotherapeutics Inc. the manager owns.